好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Resting State Functional Connectivity Correlates of Executive Function in Patients with Multiple Sclerosis
Aging, Dementia, and Behavioral Neurology
Behavioral and Cognitive Neurology Posters (7:00 AM-5:00 PM)
019

To investigate resting state (RS) functional connectivity (FC) changes in multiple sclerosis (MS) and their correlation with executive function (EF) neuropsychological measures.

EF dysfunction is a relevant disabling symptom in MS, potentially associated with brain functional reorganization.

3D T1-weighted and RS fMRI 3.0T scans were acquired from 116 MS patients and 65 healthy controls (HC). Subjects underwent neuropsychological and clinical evaluation, including computerized Wisconsin Card Sorting Test (WCST) and the Expanded Disability Status Scale (EDSS) score. RS FC was assessed using seed-voxel correlation analysis with following EF-relevant seeds: left (L) and right (R) intraparietal sulcus (IPS), frontal pole (FP) and cerebellum (Crus I and II). SPM voxel-wise models were used for RS FC between-group comparisons. Then, associations of RS FC with WCST (age- and education-corrected) and EDSS scores were evaluated.

Twenty-five (21.5%) MS patients failed at the WCST. Compared to HC, MS patients showed significantly decreased RS FC of the bilateral IPS with bilateral middle frontal, L middle temporal and L cerebellar regions, as well as increased RS FC with bilateral thalami. MS patients also exhibited decreased RS FC between L-FP and superior parietal regions. A widespread RS FC decrease was found in MS vs HC between L- and R-Crus I/II and bilateral cerebellar regions and fronto-parietal cortices. Significantly increased RS FC was finally detected between L- and R-Crus I/II and bilateral orbitofrontal cortex. In MS, significantly increased RS FC between R-Crus I/II regions and the orbitofrontal cortex was associated with better WCST performances (r=range 0.19/0.27, p=range 0.03-0.003), while decreased fronto-cerebellar and parieto-cerebellar RS FC was correlated with a higher EDSS score (r=range -0.19/-0.35, p=range 0.01-<0.001).

In an MS group relatively spared by EF deficits, increased RS FC in EF-related networks was associated with better WCST scores, suggesting a compensatory role of RS FC abnormalities.

Authors/Disclosures
Paolo Preziosa (Ospedale San Raffaele)
PRESENTER
Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bristol Myers Squibb . Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi Genzyme. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Mr. Preziosa has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.
No disclosure on file
Paola Valsasina No disclosure on file
No disclosure on file
Damiano Mistri, MSC (Università Vita-Salute San Raffaele) Mr. Mistri has nothing to disclose.
Maria A. Rocca (Neuroimaging Research Unit) Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Bristol Myers Squibb, Eli Lilly, Janssen, Roche. Maria Assunta Rocca has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AstraZaneca, Biogen, Bristol Myers Squibb, Bromatech, Celgene, Genzyme, Horizon Therapeutics Italy, Merck Serono SpA, Novartis, Roche, Sanofi and Teva. The institution of Maria Assunta Rocca has received research support from MS Society of Canada, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.
Massimo Filippi, MD, FAAN (Ospedale San Raffaele, Neuroimaging Research Unit) Dr. Filippi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion, Almirall, Biogen, Merck, Novartis, Roche, Sanofi. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion, Biogen, Bristol-Myers Squibb, Merck, Novartis, Roche, Sanofi, Sanofi-Aventis, Sanofi-Genzyme, Takeda. Dr. Filippi has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer, Biogen, Celgene, Chiesi Italia SpA, Eli Lilly, Genzyme, Janssen, Merck-Serono, Neopharmed Gentili, Novartis, Novo Nordisk, Roche, Sanofi, Takeda, and TEVA. Dr. Filippi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer Nature. The institution of Dr. Filippi has received research support from Biogen Idec, Merck-Serono, Novartis, Roche, the Italian Ministry of Health, the Italian Ministry of University and Research, and Fondazione Italiana Sclerosi Multipla.